Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13947533 | 0.83 | HTR6 (0.48) | HTR6KMT2AMAPTMEN1PTGDR2 | |
| SCHEMBL9949066 | 0.80 | SLC9A1 (0.50) | HTR6MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3030572 | 0.77 | PPARG (0.62) | HTR6KMT2AMAPTALDH1A1PTGDR2 | |
| SCHEMBL6962516 | 0.76 | MAPT (0.45) | HTR6KMT2AMAPTKDM4EMEN1 | |
| SCHEMBL6975027 | 0.76 | HTR6 (0.45) | HTR6KMT2AMAPTKDM4EMEN1 | |
| SCHEMBL6969933 | 0.76 | ALDH1A1 (0.45) | HTR6KMT2AMAPTKDM4EMEN1 | |
| SCHEMBL9949091 | 0.75 | HTR6 (0.72) | HTR6PPARGPPARDPPARA | |
| SCHEMBL16099804 | 0.75 | HTR6 (0.47) | HTR6KMT2AMAPTKDM4EMEN1 | |
| SCHEMBL6977585 | 0.75 | MAPT (0.47) | HTR6KMT2AMAPTKDM4EMEN1 | |
| SCHEMBL6977194 | 0.75 | HTR6 (0.45) | HTR6KMT2AMAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | TACR2, TACR1, AGTR1 | HTR6 1928/4885KMT2A 1555/4885MAPT 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.